Bubs Australia secures permanent US FDA approval as shares surge

Bubs Australia has received permanent U.S. Food and Drug Administration authorization for its Bubs Goat, Bubs 365 Day Grass Fed and Bubs Essential infant formulas, replacing temporary access granted during the 2022 shortage. The approval gives the Australian company a durable foothold in the highly regulated U.S. market, where its products are already sold in more than 10,000 stores. Investors responded by sending Bubs shares sharply higher, with the company highlighting opportunities for expanded retail partnerships, broader distribution and private-label manufacturing. The key tests now are whether the approval drives stronger sales and retailer uptake, while freight, tariff and regulatory costs ease and margins recover. Analysts also caution that Bubs continues to face cash-burn, debt and funding risks in a competitive market.